Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment sector : Communications save search
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -1.24%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
PHG | News | $20.97 -0.19% 0.0% 650K
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -1.19%
H: 0.52%
C: -0.17%
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 1.65%
H: 2.43%
C: 0.87%
reach treatment research market
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.7199 -6.18% -6.58% 880K
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
APYX MEDICAL CORPORATION SHOWCASES NEW DATA AND TREATMENT INSIGHTS AT THE RENUVION USERS’ SUMMIT
Published: 2024-04-11 (Crawled : 12:00) - apyxmedical.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
APYX | $1.495 13.26% 11.71% 190K
|
Health Technology
|
| O: 2.8%
H: 5.44%
C: 5.44%
renuvion corporation treatment medical apyx
Hyperpigmentation Treatment Market to Reach $10.5 Billion, Globally, by 2032 at 7.5% CAGR: Allied Market Research
Published: 2024-03-11 (Crawled : 14:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
reach treatment research market
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Published: 2024-02-29 (Crawled : 13:30) - globenewswire.com
SWTX | $43.37 -1.43% -1.45% 470K
|
Health Technology
|
| O: 2.2%
H: 1.21%
C: -0.85%
tumors authorization treatment application therapeutics
Myopia and presbyopia treatment market size to grow by USD 7.94 billion from 2022 to 2027, Major Vendors include AbbVie Inc., Alcon Inc. and Arctic Vision, Technavio
Published: 2024-02-28 (Crawled : 17:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -1.4%
H: 0.0%
C: -0.01%
BHC | $8.56 0.35% 0.0% 2M
|
Health Technology
|
| O: 0.11%
H: 2.23%
C: 0.11%
ALC | $79.57 -1.47% 0.0% 850K
|
Health Technology
|
| O: 4.09%
H: 1.72%
C: 1.41%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.6%
H: 0.02%
C: -1.03%
abbvie presbyopia treatment market
Harvard Eye Associates Now Offering iDose(R) TR as a New Treatment Option to Reduce Eye Pressure in Patients With Ocular Hypertension and Open-Angle Glaucoma
Published: 2024-02-20 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
glaucoma ocular offering treatment hypertension eye
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
Published: 2024-01-25 (Crawled : 12:00) - biospace.com/
RDHL | $0.415 -2.99% -3.08% 190K
|
Health Technology
|
| O: -31.9%
H: 0.61%
C: -11.68%
talicia patent treatment grant
Acute Ischemic Stroke Diagnosis and Treatment Market to Reach $9.2 Billion, Globally, by 2032 at 6.1% CAGR: Allied Market Research
Published: 2023-12-14 (Crawled : 01:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -1.89%
H: 0.0%
C: 0.0%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 1.19%
H: 3.09%
C: 1.3%
SYK | $336.85 0.58% 0.0% 1.5M
|
Health Technology
|
| O: 0.16%
H: 0.52%
C: -0.64%
MDT | $80.38 -1.12% 0.0% 5M
|
Health Technology
|
| O: 1.05%
H: 2.38%
C: 0.81%
PHG | News | $20.97 -0.19% 0.0% 650K
|
Health Technology
|
| O: 4.96%
H: 1.5%
C: 0.91%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.81%
H: 0.0%
C: 0.0%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 1.78%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 1.21%
H: 0.27%
C: -0.52%
stroke reach treatment research market
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.52%
H: 3.73%
C: 1.87%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
disease treatment collaboration teva deal
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -2.99%
H: 0.0%
C: 0.0%
PRAX | $51.07 4.57% 4.37% 140K
|
Health Technology
|
| O: -3.31%
H: 1.71%
C: -5.98%
pipeline
Non-Invasive Aesthetic Treatment Market to Reach $37.4 Billion, Globally, by 2032 at 9.2% CAGR: Allied Market Research
Published: 2023-11-28 (Crawled : 06:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -2.99%
H: 0.0%
C: 0.0%
aesthetic reach treatment research market
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
Published: 2023-11-27 (Crawled : 23:00) - globenewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -2.99%
H: 0.0%
C: 0.0%
SWTX | $43.37 -1.43% -1.45% 470K
|
Health Technology
|
| O: 10.74%
H: 16.83%
C: 7.17%
fda approval tumors treatment therapeutics
Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on Horizon
Published: 2023-09-29 (Crawled : 00:20) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
als hope treatment
Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on the Horiz...
Published: 2023-09-29 (Crawled : 21:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
als hope treatment
Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment
Published: 2023-09-19 (Crawled : 04:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 3.29%
H: 0.0%
C: 0.0%
cbl-0201 treatment study
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
Published: 2023-08-29 (Crawled : 11:00) - globenewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 1.76%
H: 0.0%
C: 0.0%
EGRX | $4.58 -3.98% -4.15% 95K
|
Health Technology
|
| O: 0.49%
H: 3.15%
C: 2.79%
ea-114 fda breast positive cancer treatment pharmaceuticals women meeting
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-24 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 1.28%
H: 0.0%
C: 0.0%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.31%
H: 0.96%
C: -1.35%
lynparza japan approved cancer treatment plus
Hoag Introduces New Precision Treatment for Prostate Cancer Patients
Published: 2023-06-27 (Crawled : 21:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
cancer treatment
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)
Published: 2023-06-07 (Crawled : 12:00) - biospace.com/
COYA | News | $8.28 3.24% 3.14% 120K
|
|
| O: 5.76%
H: 5.01%
C: 2.4%
disease biomarker alzheimer’s treatment blood imaging therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.